A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-11-27

AUTHORS

Jian Hu, Wenceng Pei, Zhenyou Jiang, Zihuang Li

ABSTRACT

BackgroundMicrowave ablation (MWA) has become an alternative treatment for unresectable hepatocellular carcinoma (HCC), but it does not eliminate the risk of recurrence and metastasis after treatment. Recent studies have demonstrated that miR-34a presents decreased gene expression in residual tumours after ablation therapy and can increase the therapeutic effect of arsenic trioxide against HCC, which brings new opportunities for HCC treatment.MethodsA pH-sensitive charge inversion material was used to construct a nanotargeted delivery system based on the synergistic effects of miR-34a and As2O3. We established in vitro and in vivo models of HCC microwave ablation and performed in-depth research on the dual-drug system to inhibit the rapid progression and induce pyroptosis in HCC cells after microwave ablation.ResultsThe antitumour effects were enhanced with the dual-drug nanoparticles relative to the single-drug formulations, and the therapeutic efficacy of the nanoparticles was more significant in a weakly acidic environment. The dual-drug nanoparticles increased the N-terminal portion of GSDME and decreased the expression of Cyt-c and c-met.ConclusionsDual-drug nanoparticles may improve the therapeutic efficacy of HCC treatment after insufficient ablation through Cyt-c and GSDME-N and decrease the expression levels of c-met. These nanoparticles are expected to provide new treatment methods for residual HCC after MWA, prolong the survival of patients and improve their quality of life. More... »

PAGES

32

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12645-021-00105-8

DOI

http://dx.doi.org/10.1186/s12645-021-00105-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1143366731


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, 510632, Guangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.258164.c", 
          "name": [
            "Department of Oncology Radiotherapy, The Second Clinical Medical College, Jinan University (Shenzhen People\u2019s Hospital), 518020, Shenzhen, China", 
            "Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, 510632, Guangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hu", 
        "givenName": "Jian", 
        "id": "sg:person.015515441725.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015515441725.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Civil Aviation Hospital of Shanghai, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Gastroenterology, Civil Aviation Hospital of Shanghai, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pei", 
        "givenName": "Wenceng", 
        "id": "sg:person.011303761022.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011303761022.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Microbiology and Immunology, College of Basic Medicine and Public Hygiene, Jinan University, 510632, Guangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.258164.c", 
          "name": [
            "Department of Oncology Radiotherapy, The Second Clinical Medical College, Jinan University (Shenzhen People\u2019s Hospital), 518020, Shenzhen, China", 
            "Department of Microbiology and Immunology, College of Basic Medicine and Public Hygiene, Jinan University, 510632, Guangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jiang", 
        "givenName": "Zhenyou", 
        "id": "sg:person.01256176633.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256176633.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology Radiotherapy, The Second Clinical Medical College, Jinan University (Shenzhen People\u2019s Hospital), 518020, Shenzhen, China", 
          "id": "http://www.grid.ac/institutes/grid.258164.c", 
          "name": [
            "Department of Oncology Radiotherapy, The Second Clinical Medical College, Jinan University (Shenzhen People\u2019s Hospital), 518020, Shenzhen, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Zihuang", 
        "id": "sg:person.013325120325.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013325120325.87"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/s41467-019-13204-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122952290", 
          "https://doi.org/10.1038/s41467-019-13204-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature15514", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023121489", 
          "https://doi.org/10.1038/nature15514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41467-019-09397-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1113379480", 
          "https://doi.org/10.1038/s41467-019-09397-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41419-019-1676-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117048443", 
          "https://doi.org/10.1038/s41419-019-1676-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncomms14128", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010163310", 
          "https://doi.org/10.1038/ncomms14128"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature22393", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085098582", 
          "https://doi.org/10.1038/nature22393"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41572-020-00240-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1134734554", 
          "https://doi.org/10.1038/s41572-020-00240-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-11-27", 
    "datePublishedReg": "2021-11-27", 
    "description": "BackgroundMicrowave ablation (MWA) has become an alternative treatment for unresectable hepatocellular carcinoma (HCC), but it does not eliminate the risk of recurrence and metastasis after treatment. Recent studies have demonstrated that miR-34a presents decreased gene expression in residual tumours after ablation therapy and can increase the therapeutic effect of arsenic trioxide against HCC, which brings new opportunities for HCC treatment.MethodsA pH-sensitive charge inversion material was used to construct a nanotargeted delivery system based on the synergistic effects of miR-34a and As2O3. We established in vitro and in vivo models of HCC microwave ablation and performed in-depth research on the dual-drug system to inhibit the rapid progression and induce pyroptosis in HCC cells after microwave ablation.ResultsThe antitumour effects were enhanced with the dual-drug nanoparticles relative to the single-drug formulations, and the therapeutic efficacy of the nanoparticles was more significant in a weakly acidic environment. The dual-drug nanoparticles increased the N-terminal portion of GSDME and decreased the expression of Cyt-c and c-met.ConclusionsDual-drug nanoparticles may improve the therapeutic efficacy of HCC treatment after insufficient ablation through Cyt-c and GSDME-N and decrease the expression levels of c-met. These nanoparticles are expected to provide new treatment methods for residual HCC after MWA, prolong the survival of patients and improve their quality of life.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12645-021-00105-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1042272", 
        "issn": [
          "1868-6958", 
          "1868-6966"
        ], 
        "name": "Cancer Nanotechnology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "dual-drug nanoparticles", 
      "nanodrug delivery systems", 
      "delivery system", 
      "hepatocellular carcinoma", 
      "dual drug systems", 
      "nanoparticles", 
      "HCC treatment", 
      "therapeutic efficacy", 
      "c-Met", 
      "microwave ablation", 
      "unresectable hepatocellular carcinoma", 
      "survival of patients", 
      "risk of recurrence", 
      "residual hepatocellular carcinoma", 
      "quality of life", 
      "new treatment methods", 
      "synergistic effect", 
      "residual tumor", 
      "single-drug formulations", 
      "acidic environment", 
      "antitumour effect", 
      "rapid progression", 
      "therapeutic effect", 
      "expression of Cyt", 
      "new opportunities", 
      "ablation therapy", 
      "alternative treatment", 
      "HCC progression", 
      "vivo model", 
      "HCC cells", 
      "arsenic trioxide", 
      "insufficient ablation", 
      "synergistic inhibition", 
      "expression levels", 
      "treatment", 
      "treatment methods", 
      "ablation", 
      "progression", 
      "efficacy", 
      "GSDME", 
      "Recent studies", 
      "gene expression", 
      "patients", 
      "carcinoma", 
      "recurrence", 
      "metastasis", 
      "expression", 
      "therapy", 
      "tumors", 
      "pyroptosis", 
      "N-terminal portion", 
      "survival", 
      "risk", 
      "vitro", 
      "MWA", 
      "inhibition", 
      "effect", 
      "prolongs", 
      "system", 
      "materials", 
      "trioxide", 
      "cells", 
      "depth research", 
      "cyt", 
      "levels", 
      "As2O3", 
      "study", 
      "life", 
      "method", 
      "environment", 
      "formulation", 
      "portion", 
      "quality", 
      "opportunities", 
      "present", 
      "research", 
      "model"
    ], 
    "name": "A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation", 
    "pagination": "32", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1143366731"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12645-021-00105-8"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12645-021-00105-8", 
      "https://app.dimensions.ai/details/publication/pub.1143366731"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_900.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12645-021-00105-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12645-021-00105-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12645-021-00105-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12645-021-00105-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12645-021-00105-8'


 

This table displays all metadata directly associated to this object as RDF triples.

191 TRIPLES      22 PREDICATES      109 URIs      94 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12645-021-00105-8 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N818ef3d5e6584a5d9053196c16f2070f
4 schema:citation sg:pub.10.1038/nature15514
5 sg:pub.10.1038/nature22393
6 sg:pub.10.1038/ncomms14128
7 sg:pub.10.1038/s41419-019-1676-0
8 sg:pub.10.1038/s41467-019-09397-2
9 sg:pub.10.1038/s41467-019-13204-3
10 sg:pub.10.1038/s41572-020-00240-3
11 schema:datePublished 2021-11-27
12 schema:datePublishedReg 2021-11-27
13 schema:description BackgroundMicrowave ablation (MWA) has become an alternative treatment for unresectable hepatocellular carcinoma (HCC), but it does not eliminate the risk of recurrence and metastasis after treatment. Recent studies have demonstrated that miR-34a presents decreased gene expression in residual tumours after ablation therapy and can increase the therapeutic effect of arsenic trioxide against HCC, which brings new opportunities for HCC treatment.MethodsA pH-sensitive charge inversion material was used to construct a nanotargeted delivery system based on the synergistic effects of miR-34a and As2O3. We established in vitro and in vivo models of HCC microwave ablation and performed in-depth research on the dual-drug system to inhibit the rapid progression and induce pyroptosis in HCC cells after microwave ablation.ResultsThe antitumour effects were enhanced with the dual-drug nanoparticles relative to the single-drug formulations, and the therapeutic efficacy of the nanoparticles was more significant in a weakly acidic environment. The dual-drug nanoparticles increased the N-terminal portion of GSDME and decreased the expression of Cyt-c and c-met.ConclusionsDual-drug nanoparticles may improve the therapeutic efficacy of HCC treatment after insufficient ablation through Cyt-c and GSDME-N and decrease the expression levels of c-met. These nanoparticles are expected to provide new treatment methods for residual HCC after MWA, prolong the survival of patients and improve their quality of life.
14 schema:genre article
15 schema:inLanguage en
16 schema:isAccessibleForFree true
17 schema:isPartOf N3530cdd6580147fd98265140e08040d6
18 N4b814dbebd004553ab070fcfe541f3ae
19 sg:journal.1042272
20 schema:keywords As2O3
21 GSDME
22 HCC cells
23 HCC progression
24 HCC treatment
25 MWA
26 N-terminal portion
27 Recent studies
28 ablation
29 ablation therapy
30 acidic environment
31 alternative treatment
32 antitumour effect
33 arsenic trioxide
34 c-Met
35 carcinoma
36 cells
37 cyt
38 delivery system
39 depth research
40 dual drug systems
41 dual-drug nanoparticles
42 effect
43 efficacy
44 environment
45 expression
46 expression levels
47 expression of Cyt
48 formulation
49 gene expression
50 hepatocellular carcinoma
51 inhibition
52 insufficient ablation
53 levels
54 life
55 materials
56 metastasis
57 method
58 microwave ablation
59 model
60 nanodrug delivery systems
61 nanoparticles
62 new opportunities
63 new treatment methods
64 opportunities
65 patients
66 portion
67 present
68 progression
69 prolongs
70 pyroptosis
71 quality
72 quality of life
73 rapid progression
74 recurrence
75 research
76 residual hepatocellular carcinoma
77 residual tumor
78 risk
79 risk of recurrence
80 single-drug formulations
81 study
82 survival
83 survival of patients
84 synergistic effect
85 synergistic inhibition
86 system
87 therapeutic effect
88 therapeutic efficacy
89 therapy
90 treatment
91 treatment methods
92 trioxide
93 tumors
94 unresectable hepatocellular carcinoma
95 vitro
96 vivo model
97 schema:name A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation
98 schema:pagination 32
99 schema:productId N7651691296a64f1e91c3aa9228102a45
100 Ndc9c426e6c55445d922c892f1094df06
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1143366731
102 https://doi.org/10.1186/s12645-021-00105-8
103 schema:sdDatePublished 2022-05-10T10:28
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N5b693a47c698457ca261ca9ecb14bf93
106 schema:url https://doi.org/10.1186/s12645-021-00105-8
107 sgo:license sg:explorer/license/
108 sgo:sdDataset articles
109 rdf:type schema:ScholarlyArticle
110 N25d09ae03f8d4415831fbf9bc3d4c4a2 rdf:first sg:person.01256176633.53
111 rdf:rest N89a061b3f67c4adca5afed997d61012c
112 N3530cdd6580147fd98265140e08040d6 schema:issueNumber 1
113 rdf:type schema:PublicationIssue
114 N4b814dbebd004553ab070fcfe541f3ae schema:volumeNumber 12
115 rdf:type schema:PublicationVolume
116 N5b693a47c698457ca261ca9ecb14bf93 schema:name Springer Nature - SN SciGraph project
117 rdf:type schema:Organization
118 N7651691296a64f1e91c3aa9228102a45 schema:name dimensions_id
119 schema:value pub.1143366731
120 rdf:type schema:PropertyValue
121 N818ef3d5e6584a5d9053196c16f2070f rdf:first sg:person.015515441725.93
122 rdf:rest Nac2f1c9b03c94eff976ca4271396d34a
123 N89a061b3f67c4adca5afed997d61012c rdf:first sg:person.013325120325.87
124 rdf:rest rdf:nil
125 Nac2f1c9b03c94eff976ca4271396d34a rdf:first sg:person.011303761022.16
126 rdf:rest N25d09ae03f8d4415831fbf9bc3d4c4a2
127 Ndc9c426e6c55445d922c892f1094df06 schema:name doi
128 schema:value 10.1186/s12645-021-00105-8
129 rdf:type schema:PropertyValue
130 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
131 schema:name Medical and Health Sciences
132 rdf:type schema:DefinedTerm
133 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
134 schema:name Oncology and Carcinogenesis
135 rdf:type schema:DefinedTerm
136 sg:journal.1042272 schema:issn 1868-6958
137 1868-6966
138 schema:name Cancer Nanotechnology
139 schema:publisher Springer Nature
140 rdf:type schema:Periodical
141 sg:person.011303761022.16 schema:affiliation grid-institutes:None
142 schema:familyName Pei
143 schema:givenName Wenceng
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011303761022.16
145 rdf:type schema:Person
146 sg:person.01256176633.53 schema:affiliation grid-institutes:grid.258164.c
147 schema:familyName Jiang
148 schema:givenName Zhenyou
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256176633.53
150 rdf:type schema:Person
151 sg:person.013325120325.87 schema:affiliation grid-institutes:grid.258164.c
152 schema:familyName Li
153 schema:givenName Zihuang
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013325120325.87
155 rdf:type schema:Person
156 sg:person.015515441725.93 schema:affiliation grid-institutes:grid.258164.c
157 schema:familyName Hu
158 schema:givenName Jian
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015515441725.93
160 rdf:type schema:Person
161 sg:pub.10.1038/nature15514 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023121489
162 https://doi.org/10.1038/nature15514
163 rdf:type schema:CreativeWork
164 sg:pub.10.1038/nature22393 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085098582
165 https://doi.org/10.1038/nature22393
166 rdf:type schema:CreativeWork
167 sg:pub.10.1038/ncomms14128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010163310
168 https://doi.org/10.1038/ncomms14128
169 rdf:type schema:CreativeWork
170 sg:pub.10.1038/s41419-019-1676-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1117048443
171 https://doi.org/10.1038/s41419-019-1676-0
172 rdf:type schema:CreativeWork
173 sg:pub.10.1038/s41467-019-09397-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113379480
174 https://doi.org/10.1038/s41467-019-09397-2
175 rdf:type schema:CreativeWork
176 sg:pub.10.1038/s41467-019-13204-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122952290
177 https://doi.org/10.1038/s41467-019-13204-3
178 rdf:type schema:CreativeWork
179 sg:pub.10.1038/s41572-020-00240-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1134734554
180 https://doi.org/10.1038/s41572-020-00240-3
181 rdf:type schema:CreativeWork
182 grid-institutes:None schema:alternateName Department of Gastroenterology, Civil Aviation Hospital of Shanghai, Shanghai, China
183 schema:name Department of Gastroenterology, Civil Aviation Hospital of Shanghai, Shanghai, China
184 rdf:type schema:Organization
185 grid-institutes:grid.258164.c schema:alternateName Department of Microbiology and Immunology, College of Basic Medicine and Public Hygiene, Jinan University, 510632, Guangzhou, China
186 Department of Oncology Radiotherapy, The Second Clinical Medical College, Jinan University (Shenzhen People’s Hospital), 518020, Shenzhen, China
187 Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, 510632, Guangzhou, China
188 schema:name Department of Microbiology and Immunology, College of Basic Medicine and Public Hygiene, Jinan University, 510632, Guangzhou, China
189 Department of Oncology Radiotherapy, The Second Clinical Medical College, Jinan University (Shenzhen People’s Hospital), 518020, Shenzhen, China
190 Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, 510632, Guangzhou, China
191 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...